Liraglutide
Liraglutide is studied as a glp-1 receptor agonist (acylated glp-1 analogue) in biochemical and physiological models.
Liraglutide Biological Classification
Investigated within physiological and chemical models.
What kind of compound
Peptide
GLP-1 receptor agonist (acylated GLP-1 analogue).
Human testing on file
0human records
0 animal · 0 total indexed. No plain-English evidence summary on file.
Regulatory position
FDA-approved drug substance
Studied for
Incretin analogues
Reviewed 15 September 2026
Known safety concerns in this file
- No sourced human safety summary is recorded for this compound.
Commonly compared with
No comparison set is recorded for this compound yet.
Open side-by-side comparison →What is Liraglutide?
Liraglutide is classified as a glp-1 receptor agonist (acylated glp-1 analogue). An approved acylated GLP-1 receptor agonist and an earlier Novo Nordisk analogue than semaglutide. Generic versions are listed in Drugs@FDA, and FDA named liraglutide with semaglutide and tirzepatide in its April 2026 proposal on the 503B bulks list.
Why are people interested in it?
Researchers and clinicians study Liraglutide primarily to understand its biological interactions, receptor binding affinity, and potential role within its biochemical class.
Primary Research Categories
- Incretin analogues
- Approved drug substances
How does it work in the body?
Liraglutide interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a glp-1 receptor agonist (acylated glp-1 analogue).
Biological Pathway Overview
Liraglutide Receptor & Target Interactions
This compound is evaluated in scientific research for its interactions with target cellular receptors and signaling cascades. Consult the evidence section below for specific peer-reviewed papers.
Target Pathway
Engages specific cellular signaling cascades characteristic of its structural family.
Endocrine/Paracrine Activity
Investigated for its regulatory effects on local tissue synthesis and cellular signaling.
What has actually been demonstrated in humans?
Evidence for Liraglutide is currently derived primarily from laboratory or preclinical models. Consult the published evidence file for specific indexed studies.
Pharmaceutical Reality vs. Unregulated Research Chemicals
Liraglutide is not an FDA-approved medication. Always verify chemical identity and testing documentation before interpreting research literature.
What is still uncertain or unknown?
Controlled human clinical trials evaluating Liraglutide for therapeutic efficacy, safety, and pharmacokinetics are limited or absent in peer-reviewed Western registries.
Companion Resources & Guides
Clinical Perspectives & Expert Discussions
Explore all perspectivesWhat identifiable clinicians, researchers, and professional bodies have publicly discussed regarding Liraglutide.
The Endocrine Society
Global medical organization representing over 18,000 endocrinologists, researchers, and clinical educators.
Consensus clinical guidelines recommend high-potency incretin receptor agonists (semaglutide, tirzepatide) as foundational adjuncts to lifestyle intervention for adults with obesity or weight-related comorbidities. The guideline emphasizes structured monthly dose escalation, long-term adherence to sustain metabolic benefits, and cautions against abrupt discontinuation, which typically results in weight regain.
Dosing Reference
Open Liraglutide Dosing ReferenceAn approved drug with a labelled dose schedule. The label is the authoritative source; research-chemical copies of liraglutide are not the labelled product.
Therapept separates official product labels, published clinical study interventions, animal research, clinical references, and community-reported ranges — never blended into one number.
Research at a Glance
Open the full evidence file (0 records)No evidence records in this file yet.
What Has Actually Been Studied
What is Still Unknown
What we know
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
Preparation and Handling
Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.
United States Regulatory Status
FDA-approved drug substance
Application: NDA 022341 (VICTOZA), NDA 206321 (SAXENDA); abbreviated applications for generic liraglutide
Approved Indication: Marketed in the United States as VICTOZA (glycaemic control in type 2 diabetes mellitus, and reduction of major adverse cardiovascular event risk in adults with type 2 diabetes and established cardiovascular disease) and SAXENDA (weight reduction and long-term maintenance in specified adult and paediatric populations). Generic liraglutide products are also approved.
- VICTOZA, NDA 022341, approved 25 January 2010. SAXENDA, NDA 206321, approved 23 December 2014. Both are listed as prescription products in Drugs@FDA.
- Drugs@FDA lists abbreviated new drug applications for generic liraglutide, the earliest dated 23 December 2024.
- FDA proposed in April 2026 to exclude liraglutide, semaglutide and tirzepatide from the 503B bulks list.
- Not named on the WADA 2026 Prohibited List.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
- Molecular weight
- 3751.2 Da (FDA label); 3751 g/mol (PubChem)
- Sequence length
- 181 chars
- CAS number
- 204656-20-2
- PubChem CID
- 16134956
- Compound class
- GLP-1 receptor agonist (acylated GLP-1 analogue)
- Sequence
- GLP-1(7-37) analogue with arginine substituted for lysine at position 34 and a C-16 palmitic acid attached through a glutamic acid spacer to lysine 26, as described in the FDA label
- Molecular formula
- C172H265N43O51
- Molecular weight
- 3751.2 Da (FDA label); 3751 g/mol (PubChem)
- CAS number
- 204656-20-2
- PubChem CID
- 16134956
Sources
Last reviewed 15 September 2026 · Compiled by Therapept Editorial · How these records are built